SG10201811584RA - Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof - Google Patents
Secondary Structure Stabilized NMDA Receptor Modulators And Uses ThereofInfo
- Publication number
- SG10201811584RA SG10201811584RA SG10201811584RA SG10201811584RA SG10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA
- Authority
- SG
- Singapore
- Prior art keywords
- nmda receptor
- secondary structure
- receptor modulators
- structure stabilized
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30347210P | 2010-02-11 | 2010-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811584RA true SG10201811584RA (en) | 2019-01-30 |
Family
ID=44368160
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012059358A SG183265A1 (en) | 2010-02-11 | 2011-02-11 | Secondary structure stabilized nmda receptor modulators and uses thereof |
| SG10201501050RA SG10201501050RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
| SG10201811584RA SG10201811584RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012059358A SG183265A1 (en) | 2010-02-11 | 2011-02-11 | Secondary structure stabilized nmda receptor modulators and uses thereof |
| SG10201501050RA SG10201501050RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9101612B2 (enExample) |
| EP (1) | EP2542254B1 (enExample) |
| JP (4) | JP5928828B2 (enExample) |
| CN (2) | CN102933226A (enExample) |
| AU (1) | AU2011215704B2 (enExample) |
| BR (1) | BR112012020142A2 (enExample) |
| CA (1) | CA2789331C (enExample) |
| ES (1) | ES2706063T3 (enExample) |
| IL (1) | IL221400A (enExample) |
| MX (1) | MX2012009388A (enExample) |
| RU (1) | RU2566821C2 (enExample) |
| SG (3) | SG183265A1 (enExample) |
| WO (1) | WO2011100585A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN102933226A (zh) | 2010-02-11 | 2013-02-13 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| WO2014120786A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SI2951183T1 (sl) | 2013-01-29 | 2019-07-31 | Aptinyx Inc. | Spiro-laktam NMDA receptorski modulatorji in njihove uporabe |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| US9738650B2 (en) | 2013-01-29 | 2017-08-22 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2014120784A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| EP3062810A4 (en) * | 2013-10-28 | 2017-05-03 | Naurex Inc. | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| BR112016024841A2 (pt) * | 2014-04-25 | 2017-10-24 | Naurex Inc | composições estáveis de peptídeos neuroativos |
| EP3157943A4 (en) * | 2014-06-23 | 2018-01-24 | Northwestern University | Methods of treating or ameliorating migraine |
| JP2017525684A (ja) * | 2014-07-24 | 2017-09-07 | ノーレックス インコーポレイテッド | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
| ES2822830T3 (es) * | 2015-10-14 | 2021-05-05 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| WO2017066366A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CA3002070A1 (en) * | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| US20210198315A1 (en) * | 2016-02-01 | 2021-07-01 | Naurex, INC | Process for synthesis of peptide compounds |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2018026763A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| MX383650B (es) | 2016-08-01 | 2025-03-14 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| SG11201900554YA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same |
| JP7032378B2 (ja) | 2016-08-01 | 2022-03-08 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| US20210047324A1 (en) * | 2018-01-31 | 2021-02-18 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN112204031B (zh) | 2018-01-31 | 2024-05-24 | 元羿生物科技(香港)有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| CN110003309B (zh) * | 2019-04-09 | 2021-09-10 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
| CN114599354A (zh) * | 2019-08-01 | 2022-06-07 | 阿普廷伊克斯股份有限公司 | 与nmda受体相互作用的抗体的水平升高相关性障碍的治疗方法 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CN114957445B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用 |
| CN114957444B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar的nr1亚基缺失突变体、突变体细胞及构建方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683221A (en) | 1986-01-09 | 1987-07-28 | Scripps Clinic And Research Foundation | Lymphocyte-activating polypeptides |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
| JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| CN1130372C (zh) | 1996-06-07 | 2003-12-10 | 曾尼卡有限公司 | 肽衍生物 |
| JP2000503860A (ja) | 1996-08-02 | 2000-04-04 | ザイモジェネティクス，インコーポレイティド | 精巣―特異的インシュリン同族体ポリペプチド |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| US6897028B1 (en) | 1997-07-07 | 2005-05-24 | Florida State University | Identification of molecular targets |
| WO1999002733A1 (en) * | 1997-07-07 | 1999-01-21 | Florida State University | Identification of molecular targets |
| AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| WO2001036685A2 (en) | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| JP2003521247A (ja) | 2000-02-01 | 2003-07-15 | エージーワイ セラピューティクス インコーポレーテッド | Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用 |
| WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| JP2004500874A (ja) | 2000-06-22 | 2004-01-15 | ニクシス ニューロセラピーズ インコーポレーティッド | 低酸素症および関連状態の治療のための神経活性ペプチド |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| WO2002096930A2 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| AU2002236608A1 (en) | 2000-12-14 | 2002-06-24 | Nyxis Neurotherapies, Inc. | High throughput assay to detect inhibitors of the map kinase pathway |
| AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
| WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2005014797A2 (en) | 2003-08-08 | 2005-02-17 | The Burnham Institute | P16 mediated regulation of nmda receptors |
| US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| WO2007025141A2 (en) | 2005-08-26 | 2007-03-01 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
| US8507439B2 (en) * | 2005-08-29 | 2013-08-13 | Angela Shashoua | Neuroprotective and neurorestorative method and compositions |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2008033464A2 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| JP5728752B2 (ja) | 2008-08-07 | 2015-06-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 大環状化合物の製造方法 |
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| KR20110099730A (ko) | 2008-12-15 | 2011-09-08 | 칼피스가부시키가이샤 | 피부 노화 억제 펩타이드 |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| PL2985032T3 (pl) | 2009-10-05 | 2019-07-31 | Northwestern University | Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| ME02421B (me) * | 2009-12-17 | 2016-09-20 | Merck Sharp & Dohme | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida |
| CN102933226A (zh) | 2010-02-11 | 2013-02-13 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20140107037A1 (en) | 2011-04-27 | 2014-04-17 | Northwestern University | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| US8795919B2 (en) | 2011-11-29 | 2014-08-05 | Societe BIC & Sanyo Electric Co., Ltd. | Fuel cell layer |
-
2011
- 2011-02-11 CN CN2011800146633A patent/CN102933226A/zh active Pending
- 2011-02-11 AU AU2011215704A patent/AU2011215704B2/en active Active
- 2011-02-11 CA CA2789331A patent/CA2789331C/en active Active
- 2011-02-11 SG SG2012059358A patent/SG183265A1/en unknown
- 2011-02-11 US US13/578,189 patent/US9101612B2/en active Active
- 2011-02-11 MX MX2012009388A patent/MX2012009388A/es active IP Right Grant
- 2011-02-11 BR BR112012020142-5A patent/BR112012020142A2/pt not_active Application Discontinuation
- 2011-02-11 JP JP2012553046A patent/JP5928828B2/ja active Active
- 2011-02-11 SG SG10201501050RA patent/SG10201501050RA/en unknown
- 2011-02-11 RU RU2012138710/04A patent/RU2566821C2/ru active
- 2011-02-11 CN CN201510222007.2A patent/CN105037492A/zh active Pending
- 2011-02-11 ES ES11761468T patent/ES2706063T3/es active Active
- 2011-02-11 SG SG10201811584RA patent/SG10201811584RA/en unknown
- 2011-02-11 EP EP11761468.5A patent/EP2542254B1/en active Active
- 2011-02-11 WO PCT/US2011/024583 patent/WO2011100585A1/en not_active Ceased
-
2012
- 2012-08-09 IL IL221400A patent/IL221400A/en active IP Right Grant
-
2015
- 2015-05-14 US US14/712,481 patent/US9593145B2/en active Active
-
2016
- 2016-04-13 JP JP2016080043A patent/JP6328169B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-17 JP JP2018079295A patent/JP2018119004A/ja not_active Withdrawn
-
2020
- 2020-03-17 JP JP2020046041A patent/JP2020117510A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105037492A (zh) | 2015-11-11 |
| CA2789331A1 (en) | 2011-08-18 |
| US9593145B2 (en) | 2017-03-14 |
| CA2789331C (en) | 2017-11-07 |
| JP6328169B2 (ja) | 2018-05-23 |
| IL221400A0 (en) | 2012-10-31 |
| RU2566821C2 (ru) | 2015-10-27 |
| US20160115197A1 (en) | 2016-04-28 |
| EP2542254B1 (en) | 2018-09-26 |
| EP2542254A1 (en) | 2013-01-09 |
| AU2011215704B2 (en) | 2015-07-23 |
| WO2011100585A1 (en) | 2011-08-18 |
| JP5928828B2 (ja) | 2016-06-01 |
| SG10201501050RA (en) | 2015-04-29 |
| IL221400A (en) | 2016-07-31 |
| ES2706063T3 (es) | 2019-03-27 |
| MX2012009388A (es) | 2012-10-01 |
| BR112012020142A2 (pt) | 2020-08-18 |
| EP2542254A4 (en) | 2013-07-10 |
| US20130053325A1 (en) | 2013-02-28 |
| CN102933226A (zh) | 2013-02-13 |
| US9101612B2 (en) | 2015-08-11 |
| AU2011215704A1 (en) | 2012-08-30 |
| JP2016185948A (ja) | 2016-10-27 |
| JP2013519683A (ja) | 2013-05-30 |
| JP2018119004A (ja) | 2018-08-02 |
| JP2020117510A (ja) | 2020-08-06 |
| SG183265A1 (en) | 2012-09-27 |
| RU2012138710A (ru) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811584RA (en) | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof | |
| WO2013063120A3 (en) | Nmda receptor modulators and uses thereof | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| MX2013003309A (es) | Compuestos de benzamida sustituidos. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP2571357A4 (en) | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
| IL204785A0 (en) | Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions | |
| IN2012DN01961A (enExample) | ||
| MX2015009778A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| IN2014CN04014A (enExample) | ||
| MX2013006595A (es) | Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias. | |
| MX354734B (es) | Modulación de dineína en la piel. | |
| WO2012098281A3 (es) | Péptidos moduladores de receptores trp y sus usos | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| MX2009006812A (es) | Moduladores del receptor c3a y metodos de uso de los mismos. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2010001187A (es) | Moduladores del receptor ccr9 y metodos para su uso. | |
| WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity |